本文關鍵詞： 骨髓增生異常綜合征 DNA甲基化 多基因甲基化 預后價值　出處：《中國實驗血液學雜志》2017年04期 　論文類型：期刊論文

【摘要】：目的:分析p15、DAPK、SOCS1和FHIT基因在骨髓增生異常綜合征(MDS)患者中的甲基化狀況,探討基因甲基化在MDS中的預后價值。方法:應用甲基化特異性PCR(MSP)對67例MDS患者骨髓進行上述4種基因甲基化的檢測,選擇18例缺鐵性貧血患者作為對照,分析MDS患者基因甲基化狀況及其對生存率的影響。結果:67例M DS患者中p15、DAPK、SOCS1和FHIT 4種基因甲基化率分別為37.3%、35.8%、47.8%和52.2%,較對照組顯著增高(P0.05);隨著國際預后積分系統(tǒng)(IPSS)評分的增加,p15、SOCS1基因甲基化率呈增高趨勢(P0.05),同時表達≥2個基因甲基化更易見于相對高危組患者(P0.05)。生存分析顯示,有基因甲基化和無基因甲基化患者的中位生存時間分別為15和21個月(P0.05),在相對低危組中SCOS1基因甲基化患者生存時間短于非甲基化患者(P0.05),在相對高危組中SOCS1、p15及≥2個基因甲基化患者生存時間明顯短于非甲基化患者(P0.05)。多因素分析顯示,SOCS1及p15基因甲基化是MDS患者預后不良的影響因素。結論:p15、DAPK、SOCS1和FHIT是M DS中出現(xiàn)較高的甲基化基因,SOCS1及p15基因甲基化是M DS患者不良預后的獨立危險因素。
[Abstract]:Objective: to analyze the methylation of p15 DAPKG SOCS1 and FHIT gene in patients with myelodysplastic syndrome (MDS). To evaluate the prognostic value of gene methylation in MDS methods: methylation specific PCR- MSPs were used to detect the methylation of bone marrow of 67 patients with MDS. Eighteen patients with iron deficiency anemia were selected as control group to analyze the status of gene methylation and its influence on survival rate in MDS patients. Results p15DAPK was found in 67 patients with MDS. The methylation rates of SOCS1 and FHIT were 37.3% and 52.2%, respectively, which were significantly higher than those of the control group (P 0.05). With the increase of IPSS score, the methylation rate of p15 SOCS1 gene showed an increasing trend (P0.05). At the same time, the methylation of more than 2 genes was more easily seen in the patients with higher risk group (P 0.05). Survival analysis showed that methylation of more than 2 genes was more common. The median survival time of patients with and without gene methylation was 15 and 21 months respectively (P0.05). The survival time of SCOS1 gene methylation patients was shorter than that of demethylated patients in the relatively low risk group, and SOCS1 was found in the relatively high risk group. The survival time of p15 and 鈮，

本文編號：1489759